TONMYA (Cyclobenzaprine Hydrochloride) Patent Expiration, LOE Window & CMS Spending

TONMYA (Cyclobenzaprine Hydrochloride) by Tonix: FDA Orange Book core substance LOE 2034-03-14, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $1,860 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTonix
FDA Application & PathwayN219428 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-03-14
Last Listed Patent or Exclusivity Date2034-03-14
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,860 intro WAC)